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Our objective was to illustrate the potential of metabolomics to identify novel biomarkers of illness
severity in a child with fatal necrotizing pneumonia caused by methicillin-resistant Staphylococcus aur-
eus (MRSA). We present a case report with two control groups and a metabolomics analysis: an infant
with fatal MRSA pneumonia, four children with influenza pneumonia (pneumonia control group), and
seven healthy children with no known infections (healthy control group). Urine samples were col-
lected from all children. Metabolites were identified and quantified using 1H-nuclear magnetic reso-
nance spectrometry. Normalized metabolite concentration data from children with influenza
pneumonia and healthy controls were compared by using an unpaired Student t test. To identify differ-
entiating metabolites of MRSA pneumonia, the fold change of each metabolite was calculated by divid-
ing each urine metabolite concentration of the patient with fatal MRSA pneumonia by the median
urine concentration values of the same metabolite of the patients with influenza pneumonia and
healthy controls, respectively. MetScape (http://metscape.ncibi.org/), a bioinformatics tool, was used
for data visualization and interpretation. Urine metabolite concentrations previously identified as asso-
ciated with sepsis in children (e.g., 3-hydroxybutyrate, carnitine, and creatinine) were higher in the
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C A S E R E P O R T
patient with fatal MRSA pneumonia compared with those of patients with influenza pneumonia and
healthy controls. The concentrations of additional metabolites—acetone, acetoacetate, choline,
fumarate, glucose, and 3-aminoisobutyrate—were more than 25-fold higher in the patient with MRSA
pneumonia than those of patients with influenza pneumonia and healthy controls. These metabolic
changes in the urine preceded the clinical severe sepsis phenotype, suggesting that detection of the
extent of metabolic disruption can aid in the early identification of a sepsis phenotype in advance of
the clinical diagnosis. These data also support the utility of metabolomics for the development of clini-
cal assays to identify patients with pediatric pneumonia at high risk for deterioration.
KEY WORDS metabolomics, pediatrics, septic shock, necrotizing pneumonia, nuclear magnetic
resonance.
(Pharmacotherapy 2017;37(9):1033–1042) doi: 10.1002/phar.1973
Community-acquired pneumonia (CAP), a
common cause of hospitalization among children,
may be accompanied by complications within the
pulmonary cavity, such as necrotizing pneumo-
nia.1–3 Some children with CAP may also develop
serious systemic complications such as sepsis.
Identifying children with CAP who are at high risk
for sepsis and subsequent clinical deterioration is
challenging. For example, the first vital sign con-
sistent with the criteria for systemic inflammatory
response syndrome (SIRS)4 that needs to be met
for a sepsis diagnosis occurs in more than 90% of
pediatric patients with fever (higher than 38.5°C)
who visit the emergency department (ED). Of
these patients, 82% are discharged from the ED
without intravenous therapy and do not revisit the
ED, whereas only 0.25% of these patients require
critical care in the first 24 hours. Therefore, the
SIRS criteria alone are insufficient to identify
patients at risk of deterioration because these crite-
ria have poor specificity in predicting the need for
critical care in children.5 Although sepsis criteria
have greater specificity, childrenmay quickly dete-
riorate once these criteria are met, illustrating the
great need for a tool that can predict the severity of
the clinical course of disease before the patient
deteriorates.4, 5
Metabolomics, the study of small molecules
(smaller than 1 kDa), may provide a real-time
snapshot of the biochemical impact of disease
on the host. The objective of this study was to
illustrate the use of metabolomics in identifying
a patient at high risk for deterioration before
meeting the clinical criteria of sepsis, identifying
the source of infection through conventional
microbiologic techniques, and the diagnosis of a
rare complication of pneumonia. Specifically,
our aim was to identify novel biomarkers of ill-
ness severity in a child with fatal necrotizing
pneumonia caused by methicillin-resistant Sta-
phylococcus aureus (MRSA).
Methods
Study Design and Patient Population
In this case report with a metabolomics analy-
sis, two sets of controls were used for comparison
with the patient with fatal MRSA pneumonia. The
first set consisted of children diagnosed with
influenza pneumonia (pneumonia controls), and
the second set consisted of children who had no
known infection (healthy controls). The children
enrolled provided written assent (if applicable),
and their parents or legal guardians provided
written consent according to the study protocol
approved by the institutional review board at
Cincinnati Children’s Hospital Medical Center
(Cincinnati, OH).
Patient with Fatal MRSA Pneumonia
A previously healthy, fully immunized 8-
month-old infant presented to the ED of a ter-
tiary care children’s hospital after experiencing
3 days of fever (maximum temperature 39.8°C),
cough, difficulty breathing, emesis, diarrhea, rhi-
norrhea, and fatigue. Five hours after ED arrival,
the infant was enrolled in Catalyzing Ambula-
tory Research in Pneumonia Etiology and Diag-
nostic Innovations in Emergency Medicine
(CARPE DIEM), a research study investigating
the severity and etiology of pediatric pneumonia.
The infant had no significant medical or family
history. On ED arrival, the infant’s vital signs
were a heart rate of 208 beats/minute, rectal
temperature 39.8°C, respiratory rate 50 breaths/
minute, blood pressure 131/71 mm Hg, and
room air oxygen saturation of 94% as measured
by pulse oximetry (Figure 1). Physical examina-
tion revealed an ill, but not toxic-appearing,
infant in moderate respiratory distress. Mild sub-
costal and intercostal retractions and diffuse
1034 PHARMACOTHERAPY Volume 37, Number 9, 2017
rhonchi were present. The infant was well per-
fused, with a capillary refill time less than 2 sec-
onds. Initial diagnostic evaluation included a
complete blood count significant for a white
blood cell count of 1100 cells/mm3 and an abso-
lute neutrophil count of 80 cells/mm3; a blood
culture revealed no growth of an organism after
5 days of incubation (Table 1). The chest radio-
graph was concerning for multifocal pneumonia
(Figure 2A). Serum electrolyte and blood urea
nitrogen (BUN) levels were normal for the
infant’s age. A rapid venous blood gas was per-
formed that returned a mild base deficit
(4 mmol/L [normal range 2 to 2 mmol/L]).
Due to concerns for bacterial pneumonia, the
infant received a dose of ampicillin 50 mg/kg in
the ED according to national guidelines.6 The
patient was admitted to the intensive care unit
(ICU) because of increased respiratory distress,
and a regimen of ceftriaxone (50 mg/kg) was
initiated, of which one dose was administered,
to provide broader empirical coverage. The
infant deteriorated rapidly, progressing to respi-
ratory failure requiring intubation, during which
he suffered cardiac arrest requiring extracorpo-
real membrane oxygenation. At this time, a new
pleural effusion was discovered, requiring a tube
thoracotomy (Figure 2B), and the patient was
formally diagnosed with sepsis (Figure 1).7 Gen-
tamicin (25 mg/kg) was initiated, then van-
comycin (135 mg was dosed intermittently) and
piperacillin/tazobactam (100 mg/kg every
6 hours) were initiated to provide broader
antibiotic coverage. Despite these efforts, there
Figure 1. Timeline of the clinical course of the patient with fatal methicillin-resistant Staphylococcus aureus pneumonia. The
dashed box indicates that systemic inflammatory response syndrome criteria were met, and the solid box indicates sepsis
criteria were met. Information about antibiotic regimens can be found in the text. ANC = absolute neutrophil count;
BP = blood pressure; CARPE DIEM = Catalyzing Ambulatory Research in Pneumonia Etiology and Diagnostic Innovations in
Emergency Medicine; CBC = complete blood count; ECMO = extracorporeal membrane oxygenation; ED = emergency
department; HR = heart rate; ICU = intensive care unit; NP = nasopharyngeal; PCR = polymerase chain reaction;
RR = respiratory rate; SpO2 = oxygen saturation; WBC = white blood cell count. *Results from the i-STAT venous point-of-
care blood gas, renal panel, viral respiratory PCR panel, and the CBC with differential can be found in the text and Table 1.
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was no improvement, and care was withdrawn;
the infant died 43.2 hours after admission to the
ICU. The cause of death on autopsy was severe
necrotizing and hemorrhagic pneumonia caused
by S. aureus infection, determined by a post-
mortem respiratory culture of MRSA.
Patients with Influenza Pneumonia
The CARPE DIEM study enrolls previously
healthy children with no chronic illnesses,
3 months to 18 years of age, who present to the
ED with signs and symptoms of lower respira-
tory tract infection (e.g., cough, chest pain, dys-
pnea/shortness of breath) and are diagnosed
with pneumonia confirmed by a focal opacity on
chest radiograph. The attending ED physician is
asked for the overall clinical impression of the
patients including the suspected probability (0–
100%) and likelihood (highly unlikely, unlikely,
likely, highly likely) that the patient would pro-
gress to severe disease or develop complications
of pneumonia. A blood, nasal swab, and urine
sample are collected at the time of enrollment. A
respiratory viral polymerase chain reaction
(PCR) panel and Mycoplasma pneumoniae PCR
are performed on the nasal swab sample. The
viral panel tests for influenza A, influenza B,
parainfluenza 1, parainfluenza 2, parainfluenza
3, respiratory syncytial virus, human metapneu-
movirus, and human enterovirus/rhinovirus.
Clinicians are blinded to the results of these
tests because they are performed for research
purposes only. Four patients enrolled in the
CARPE DIEM study who had positive influenza
PCR nasal swab results were included in this
analysis as the influenza pneumonia patient
cohort.
Healthy Controls
The healthy control cohort was part of a
cross-sectional population study entitled the
Genomic Control Cohort (GCC), conducted
between 2007 and 2010.8 In the GCC study,
urine samples were collected from healthy chil-
dren, 3–18 years of age, living within the greater
Cincinnati region. Seven urine samples from the
GCC were age range and sex matched to the
patients with influenza pneumonia included in
the analysis.
Urine Sample Collection
Urine samples were collected in specimen col-
lection cups coated with 10% sodium azide
Table 1. Demographic and Clinical Characteristics of the Three Patient Groups
Characteristic
Patient with fatal
MRSA pneumoniaa
Patients with
influenza
pneumonia (n=4)a
Healthy
controls (n=7)
Age, yrs 0.67 9.5 (7.5–11.4) 9.0 (7.5–11.0)
Male sex 1 (100) 2 (50) 4 (57.1)
White 1 (100) 4 (100) 5 (71.4)
Non-Hispanic ethnicity 1 (100) 4 (100) 7 (100)
BMI (z score)b 0.98 0.30 (0.79 to 1.89) 0.55 (1.47 to 2.10)
Vital signs
Heart rate, beats/min 208 135 (116–184) NA
Temperature, °C 39.8 37.3 (36.9–38.1) NA
Respiratory rate, breaths/min 50 36 (24–48) NA
Blood pressure, mm Hg 131/71 108/59 (93/55–117/58) NA
Oxygen saturation, % on room air 94 96 (95–97) NA
Laboratory results
White blood cell count, cells/mm3 1100 12,700 (9500–14,900) NA
Absolute neutrophil count, cells/mm3 80 10,580 (6740–13,540) NA
Blood culture No growth after 5 days No growth after 5 days NA
Creatinine level, mg/dl 0.25 NA NA
Blood urea nitrogen level, mg/dl 7 NA NA
Rapid venous blood gas, mmol/L 4 NA NA
C-reactive protein level, mg/dl 4.34 5.7 (3.37–9.55) NA
Procalcitonin level, ng/ml 14.1 0.3 (<0.1–0.4) NA
Data are mean (range) or no. (%) of patients in the influenza pneumonia and healthy control groups.
BMI = body mass index; MRSA = methicillin-resistant Staphylococcus aureus; NA = not applicable or available because these tests were not
performed as part of clinical care in any of the patients with influenza pneumonia or in the assessment of the healthy controls.
aAt the time of presentation to the emergency department.
bBMI is presented as the z score that adjusts the height and weight of a child relative to age. It is a more accurate comparison for BMI across
ages.
1036 PHARMACOTHERAPY Volume 37, Number 9, 2017
solution to inhibit bacterial growth in the sam-
ple.9 They were then centrifuged for 10 minutes,
and aliquots (1 ml) of supernatant were stored
(80C) until the time of assay.
Nuclear Magnetic Resonance Data Acquisition
and Spectral Analysis
Frozen urine samples were shipped to the
University of Michigan’s Nuclear Magnetic Reso-
nance (NMR) Metabolomics Laboratory. At the
time of the assay, samples were thawed at room
temperature. The pH of each sample was adjusted
with sodium hydroxide or hydrochloric acid
to achieve a pH of 7.0  0.25.10 A volume equiv-
alent to 10% of the total sample volume of
5.4 mM of 4,4-dimethyl-4-silapentane-1-sulfonic
acid (DSS-d6) in deuterium oxide was added to
each sample as an internal standard. A one-
dimensional 1H-NMR spectrum of each urine
sample was acquired using the first increment of
the standard NOESY pulse sequence on a Varian
(Varian Inc., Palo Alto, CA) Inova-500 MHz
NMR spectrometer at the University of Michigan’s
Biochemical NMR Laboratory as previously
described.10–12 All spectra were recorded at 25°C.
Spectral analysis was performed using quantita-
tive metabolomics.13, 14 The raw 1H-NMR spectra
were processed using Chenomx software (NMR
Suite v.7.5; Chenomx Inc., Edmonton, AB,
Canada).10, 11 The resulting quantified metabo-
lites were standardized to urine creatinine by
dividing the concentration of each metabolite by
the associated creatinine concentration as deter-
mined from the NMR spectrum of the same
sample.15, 16 The quantified metabolite data (ex-
cluding urea) from the samples from the patient
with fatal MRSA pneumonia, patients with influ-
enza pneumonia, and healthy controls were cube
root transformed and autoscaled to achieve a
normal distribution of the data and conduct para-
metric statistical analysis.10, 17
Statistical Analysis of Metabolite Profiles
The normalized metabolite concentration data
of the healthy controls and the patients with
influenza pneumonia were compared with an
unpaired Student t test. The resulting p values
were corrected for multiple comparisons by
calculating the false discovery rate using a
previously published method.18 To identify
potentially relevant metabolites of fatal MRSA
pneumonia, the fold change of each metabolite
was calculated by dividing each urine metabolite
concentration of the patient with fatal MRSA
pneumonia by the median urine concentration
values of the same metabolite of the patients
with influenza pneumonia and healthy controls.
The resulting two lists of metabolites were each
ordered by descending fold change. The metabo-
lites with at least a 25-fold change that were
common to both lists were considered poten-
tially relevant.19 The bioinformatics tool MetS-
cape (http://metscape.ncibi.org/),20 a plugin for
the open-source network data integration tool
Figure 2. Anteroposterior chest radiographs of the patient with fatal methicillin-resistant Staphylococcus aureus pneumonia.
(A) Chest radiograph revealing multifocal pneumonia. (B) Chest radiograph revealing development of pleural effusion and
imaged after placement of endotracheal tube.
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Cytoscape (http://www.cytoscape.org/), was used
to assess visually the metabolic relationship
between the found relevant metabolites and to
construct a network figure. Statistical analyses
and the construction of bar graphs were per-
formed with PRISM v.6.0f (https://www.graph
pad.com/), and the radar plot was constructed in
Microsoft Excel (Microsoft Corp., Redmond,
WA).
Results
Based on the infant’s appearance in the ED,
the attending physician reported a 5–10% proba-
bility of this infant progressing to severe disease
or developing pneumonia complications, and felt
it would be unlikely for the patient to progress
to severe disease. As part of the research study,
procalcitonin and C-reactive protein levels were
measured and found to be elevated (14.1 ng/mL
and 4.34 mg/dL, respectively) (Table 1).21 The
PCR for Mycoplasma pneumoniae was negative.
The viral panel was positive only for respiratory
syncytial virus.
The mean age in the healthy control group
was 9.0 years (range 7.5–11.0) and 9.5 years
(range 7.5–11.4) for patients with influenza
pneumonia; the fatal MRSA pneumonia patient
was 8.4 months old. In addition, three of the
four patients with influenza pneumonia were
given one dose of antibiotics before the collec-
tion of urine: ampicillin (one patient), ceftriax-
one (one patient), and azithromycin (one
patient).
A total of 75 metabolites (including creatinine
and urea) were identified and quantified in each
urine sample. Nine metabolite concentrations
were statistically different between healthy con-
trols and patients with influenza pneumonia
(Table 2). Seven metabolite concentrations were
increased by at least 25-fold in the patient with
fatal MRSA pneumonia compared with those of
both healthy controls and patients with influ-
enza pneumonia (Table 3 and Figures S1–S5).
The magnitudes of difference in all detected
metabolites are highlighted in a radar plot of
creatinine-corrected metabolite concentrations
(Figure 3A). The seven potentially differentiat-
ing metabolites of the patient with fatal MRSA
pneumonia from healthy controls and patients
with influenza pneumonia are depicted in
Figure 3B. Concentrations of both acetylcar-
nitine and carnitine, which are vital to
energy production22 and mitochondrial metabo-
lism,23 were substantially higher in the patient
with fatal MRSA pneumonia than in either the
healthy controls or the patients with influenza
pneumonia (Figure 3B).
The most changed metabolite concentrations
from the patient with fatal MRSA pneumonia
were the ketone bodies (3-hydroxybutyrate, ace-
toacetate, and acetone) and fumarate, a tricar-
boxylic acid cycle metabolite, which are
associated with a single metabolic network (Fig-
ure 3C). Notably, the urine urea concentration
of the patient with fatal MRSA pneumonia was
lower (71,616 lM) than the median urea con-
centrations of the patients with influenza pneu-
monia (114,871, interquartile range [IQR]
97,989–165,273 lM) and healthy controls
(192,506, IQR 167,475–217,754 lM).
Discussion
This study provides evidence of the potential
of metabolomics to identify novel biomarkers of
illness severity in advance of clinical presenta-
tion and supports the need for further research
to identify and validate urinary metabolites as
potential biomarkers for early sepsis. This is evi-
denced by the increase in urine concentrations
of several metabolites associated with MRSA
infection. This finding is particularly important
because currently there are emerging clinical
biomarkers that only identify the presence of
infection (e.g., elevated white blood cell count
or C-reactive protein level) or biomarkers that
are moderately predictive of bacterial infection
and septic shock in children (e.g., procalci-
tonin level).24 However, currently available
biomarkers neither distinguish among different
etiologies (e.g., Streptococcus pneumoniae vs
MRSA) nor do they elucidate the severity of
infection.25, 26 In this case of fatal MRSA
Table 2. Candidate Differentiating Metabolites of Patients
with Influenza Pneumonia Compared with Those of
Healthy Controls
Metabolite KEGG ID p value FDR, %
Creatine C00300 0.004 28
Guanidinoacetate C00581 0.008 31
1-Methylnicotinamide C02918 0.014 34
2-Hydroxy-3-methylvalerate NA 0.018 34
Trimethylamine N-oxide C01104 0.022 34
Citrate C00158 0.029 36
N-methyl hydantoin C02565 0.042 38
Methanol C00132 0.050 38
Threonine C00188 0.050 38
FDR = false discovery rate; KEGG = Kyoto Encyclopedia of Genes
and Genomes (http://www.genome.jp/kegg/); NA = not applicable.
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pneumonia, knowledge of the metabolomics pro-
file might have helped with the timely diagnosis
of sepsis in the ED because this diagnosis can be
challenging for several reasons including the
presence of common nonspecific symptoms
(e.g., fever, tachycardia) that can occur with
more prevalent, less severe infections.27 Had the
intensity of this patient’s metabolic derangement
been known in the ED, more aggressive thera-
pies including fluid resuscitation, vasopressor
support, and broad-spectrum antibiotics could
possibly have been provided earlier in an
attempt to avert this fatal outcome.
The findings presented here corroborate and
extend the results of previous studies, one of
which recognized the utility of metabolomics as
a tool for gauging pneumonia severity.28 In that
study, children 1 month to 11 years with a
diagnosis of sepsis had elevated levels of at
least six metabolites (3-hydroxybutyrate, car-
nitine, creatinine, creatine, glucose, and ace-
tone) compared with those of healthy patients.
In addition, in adults and children, sepsis-
induced changes in levels of carnitine and
its cometabolite, acetylcarnitine, which are
involved in maintaining mitochondrial function,
may indicate mitochondrial stress or dysfunc-
tion, known to occur in sepsis.28–31 The extent
of metabolic dysfunction in our patient with
fatal MRSA pneumonia was further evidenced
by the greater than 25-fold increase in the uri-
nary excretion of ketone bodies, fumarate, and
glucose compared with those from the urine
samples from patients with influenza pneumo-
nia and healthy controls. These metabolites are
different from those identified in a previous
study of sepsis in children, most likely due to
the host’s response to both sepsis and necrotiz-
ing pneumonia.32 Importantly, in our patient,
the consequence of the high degree of meta-
bolic dysfunction was evident in the urine sam-
ple collected before the patient’s subsequent
development of severe septic shock, respiratory
failure, and, ultimately, death.
The metabolites choline and 3-aminoisobuty-
rate were also markedly increased in the patient
with fatal MRSA pneumonia when compared
with those in the two control groups. In a
mouse model, neither of these metabolites were
associated with a lung-infected mouse with
MRSA.12 However, elevated urine choline has
been associated with antibiotic administration,33
which may explain the increase in our patient
because the child’s urine sample was collected
following administration of a dose of ampicillin.
Altered 3-aminoisobutyrate homeostasis is asso-
ciated with hyper-b-aminoisobutyric aciduria,
one of the most common Mendelian metabolic
variants in humans.34 In sepsis, increased urine
3-aminoisobutyrate, an end product of nucleic
acid metabolism, may be explained by sepsis-
induced impairment of skeletal muscle uptake.35
A potential limitation of the study is the over-
all concentration of the urine samples, which is
influenced greatly by the hydration state of the
patient. However, the urea concentration in the
urine of the patient with fatal MRSA pneumonia
was lower and thus less concentrated compared
with the urea concentrations in healthy controls
and patients with influenza pneumonia. There-
fore, the less than 2-fold difference in urea con-
centration (patient with fatal MRSA pneumonia
vs patients with influenza pneumonia) does not
explain the greater than 100- to 500-fold
Table 3. Candidate Differentiating Metabolites with ≥25-Fold Change in the Patient with Fatal MRSA Pneumonia Com-
pared with the Other Patient Groups
Patient with fatal MRSA pneumonia vs healthy
controls
Patient with fatal MRSA pneumonia vs patients with
influenza pneumonia
Metabolite Fold change Metabolite Fold change
3-Hydroxybutyratea 933 3-Hydroxybutyratea 521
Acetonea 717 Acetonea 510
Ascorbate 95 Acetoacetatea 116
3-Aminoisobutyratea 70 Cholinea 58
Isobutyrate 63 Fumaratea 34
Acetoacetatea 63 3-Aminoisobutyratea 34
Fumaratea 57 Adipate 31
Glucosea 47 Glucosea 30
Cholinea 41 Azelate 27
Lactate 28 Succinate 27
2-Aminobutyrate 28 Trimethylamine N-oxide 26
MRSA = methicillin-resistant Staphylococcus aureus.
aMetabolites common to both comparisons.
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increase in ketone body concentrations in the
urine of the patient with fatal MRSA pneumonia.
In addition, the patient had no clinical signs and
symptoms of significant dehydration and did not
have prolonged capillary refill time, abnormal
skin turgor, sunken eyes, dry mucous mem-
branes, cool extremities, weak pulses, or an
absence of tears.36 Furthermore, the patient’s
laboratory values were inconsistent with
dehydration or renal dysfunction, given the
normal serum bicarbonate, BUN, and creatinine
concentrations at the time of the urine
collection.
A second potential limitation is that the patient
with fatal MRSA pneumonia was 8 months of age
compared with the patients with influenza pneu-
monia and healthy controls who were older, with
mean ages of 9.5 and 9 years, respectively
Figure 3. Influenza- and methicillin-resistant Staphylococcus aureus (MRSA)-induced distinct metabolic changes in the urine
of children compared with the urine of healthy controls. (A) A radar plot shows the magnitude of the differences in 75 urine
metabolites (log lM concentration/mM creatinine) in seven healthy children, four children with influenza, and the patient
with MRSA pneumonia. (B) Metabolite levels with at least a 25-fold difference between the patient with MRSA pneumonia
and both healthy controls and patients with influenza pneumonia are shown in order of descending fold change. Also
included are the urine concentrations of acetylcarnitine and carnitine, metabolites important in mitochondrial function,
whose elevation substantiates the magnitude of the perturbation in energy metabolism in the patient with MRSA that is
shown by the large difference in the concentrations of urine ketone bodies and glucose. Data are the median (interquartile
range). The greatest metabolic change was in ketone bodies (3-hydroxybutyrate, acetoacetate, and acetone), which is further
illustrated in the MetScape-generated network (C), which shows the relationship between the inputted compounds,
acetoacetate, 3-hydroxybutyrate, and fumarate (dark red hexagons); acetone is generated by the nonenzymatic
decarboxylation of acetoacetate so it is not shown in the network. The inputted compounds resulted in the generation of a
single compound (red hexagons)–reaction (gray squares)–enzyme (green rounded-corner squares) network. This network
map exemplifies the range of perturbation in energy metabolism because of the association between ketone bodies and
tricarboxylic acid (TCA) metabolites fumarate and succinate, the latter of which was 27-fold higher in the patient with MRSA
compared with patients with influenza pneumonia. Of note, acetyl coenzyme (CoA), which initiates the TCA cycle, is
produced via glycolysis and carnitine-mediated fatty acid oxidation.
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(Table 1). Age is known to contribute to the vari-
ance of the metabolome; however, in a recent
metabolomics study of pediatric sepsis, the mag-
nitudes of age-related metabolic differences were
much smaller than those identified in this
report.28 Patients with sepsis were categorized
into four groups including infants (1 month to
1 year) and school age (6–11 years). Identified
metabolites were grouped by these age categories,
and carnitine, creatine, and creatinine were the
only metabolite concentrations that were elevated
in school-age children but not in infants. Based
on this finding, we would expect that in our
study, in general, these metabolite levels would
be much higher in the patients with influenza
pneumonia because of their older age, but the
metabolite levels from the patient with fatal
MRSA pneumonia were always higher. Therefore,
we contend that the metabolite level differences
among our healthy controls, patients with influ-
enza pneumonia, and the patient with fatal MRSA
pneumonia cannot be explained simply based on
differences in age.
Conclusion
Quantitative 1H-NMR urine metabolomics
revealed a pattern of metabolites in a patient
with complicated necrotizing pneumonia caused
by MRSA that may serve as a potential tool to
assist in early recognition of a severe disease
course, namely septic shock. In this study, the
profound metabolic change in the patient with
fatal MRSA pneumonia was detected in the urine
sample before many of the standard clinical and
laboratory measures suggested severe sepsis. The
availability of these data in the ED may have
influenced clinical decision making and resulted
in the identification of a high-risk patient earlier
in the clinical course. However, because the clin-
ical application of metabolomics has yet to be
realized, validation of the identified metabolites
of patients with fatal MRSA pneumonia is needed
as well as further advances in technology to
develop point-of-care and/or clinical tests based
on the findings from metabolomics studies.
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Supporting Information
The following supporting information is available in the online
version of this paper:
Figure S1. The 3-hydroxybutyrate with distinct chemical shifts
at 1.19 ppm, 2.30 ppm, 2.40 ppm, and 4.14 ppm.
Figure S2. Acetone with a single peak at 2.22 ppm, and ace-
toacetate with a peak at 2.27 ppm and another at 3.44 ppm.
Figure S3. Fumarate with a single peak at 6.52 ppm, choline
with a peak at 3.19 ppm, and glucose with peaks at 3.73 ppm and
5.23 ppm.
Figure S4. 3-aminoisobutyrate with peaks at 1.18 ppm, 3.01
ppm, and 3.08 ppm.
Figure S5. O-acetylcarnitine with peaks at 2.13 ppm, 3.18 ppm,
5.60 ppm, and carnitine with a peak at 3.21 ppm.
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